Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Diagnostics › Molecular Diagnostics › Guardant Health Enters CDx Collaboration With Radius Health for Elacestrant in HER2- Breast Cancer

Guardant Health Enters CDx Collaboration With Radius Health for Elacestrant in HER2- Breast Cancer

Jul 30, 2020
|
staff reporter

NEW YORK – Guardant Health said Thursday that it is collaborating with Radius Health to pursue regulatory approval of its Guardant360 CDx assay as a companion diagnostic for elacestrant (RAD1901), an investigational selective estrogen receptor degrader being studied in the treatment of advanced ER-positive, HER2-negative breast cancers that are resistant to CDK4/6 inhibitors in combination with hormone therapy. 

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Nov
03
Featured Webinar

A Streamlined Targeted NGS Workflow for Comprehensive Genomic Profiling of Different Tumor Samples

Molecular tumor profiling has provided extensive value, both in tumor biology and oncology, with the development of new technologies to identify biomarkers.

Nov
05
Featured Webinar

Beyond Traditional Biopsy for Esophageal Cancer: Novel Sampling Methods to Improve Patient Care

This webinar will provide an overview of novel proximal and distal sampling methods that have promise to improve patient outcomes from esophageal cancer.

Nov
09
Featured Webinar

The Tumor Neighborhood Watch: How Spatial Architecture and Cellular Neighborhoods Correlate to Colorectal Cancer Outcomes

Sponsored by
Akoya Biosciences

Most recent single-cell and spatial biology studies have focused on the network of interactions between different cell types and their spatial context. 

What's Popular?

In Cancer

  1. Roche EGFR Mutation Test Approved by FDA as Companion Diagnostic for NSCLC

  2. SickKids' 'Rigorous' Molecular Analysis IDs Targetable Alterations, Cancer Susceptibility Mutations

    Premium

  3. Scorpion Therapeutics Launches With $108 Million in Series A Funding

  4. Early Data in Hand, Verastem Marches Ahead With RAF-MEK Inhibitor Program in KRAS-mutated Cancers

    Premium

  5. Epic Sciences, Predicine to Offer Liquid Biopsy Service for Biopharma Customers

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.